MEK inhibitors as a chemotherapeutic intervention in multiple myeloma.
about
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Novel therapeutic strategies for multiple myelomaActivation of non-canonical TGF-β1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis.Identification of novel inhibitors of human Chk1 using pharmacophore-based virtual screening and their evaluation as potential anti-cancer agents.Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.Multiple Myeloma: Treatment is Getting IndividualizedA DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells.RNA interference for multiple myeloma therapy: targeting signal transduction pathways.Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6.Ocular toxicities of MEK inhibitors and other targeted therapies.Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells.Prioritization of anticancer drugs against a cancer using genomic features of cancer cells: A step towards personalized medicine.Sorafenib for the treatment of multiple myeloma.Integrated Drug Expression Analysis for leukemia: an integrated in silico and in vivo approach to drug discovery.Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma.Expression of RKIP in chronic myelogenous leukemia K562 cell and inhibits cell proliferation by regulating the ERK/MAPK pathway.High Expression of Phosphorylated Extracellular Signal-Regulated Kinase (ERK1/2) is Associated with Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma.Artocarpus altilis CG-901 alters critical nodes in the JH1-kinase domain of Janus kinase 2 affecting upstream JAK/STAT3 signaling.Loss of FAM46C Promotes Cell Survival in Myeloma.Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma.Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy.
P2860
Q27692033-F4522D39-6904-49EE-900C-028AFF164F4CQ28081590-DAC8AC8D-AAC6-4C7E-AF86-CFEDAC9976B2Q35113804-20AD7A59-59E1-4A61-B059-14155ABC8DF2Q35329233-2941D6D0-8749-4DB8-A46E-C8227C67B4A3Q35859205-F2569546-E283-4DD2-9D1C-4799F09F842AQ36522964-BE8548E6-0CB5-45B6-BFEC-AF22D244468DQ37325007-5D157ACF-C8E9-472F-B996-197A954877E2Q38402255-B2B25E69-8FB2-48B5-9184-3057AB81CA24Q38550480-4AEEB625-6E16-4B06-A145-B8A65D7DF75EQ38585847-85BCC17F-8683-423F-8454-EA43BA55D77FQ38718211-EB9E22A5-80BA-4C4C-A588-47969275D057Q38764273-8D22ED25-D435-4EE8-A807-DCEEB4AAD7F8Q38765278-DB5C543A-AC87-4B42-B55F-C3DF58CB02B2Q38782268-9E40915A-E16E-4B32-8014-FD7BE6D6CB4EQ38783055-F86F6CA1-5EAE-4296-AC2A-AAEA42BE0C65Q38786554-3F2F6A6E-2CDF-4558-BB92-7118516A89D3Q38793093-ED5EECFA-EB73-4FA6-A0C3-BCF7EEE4E919Q38815363-97DCE23E-5884-4AB4-AF9D-B540BDC6904FQ39161075-6C2DB33E-79FD-4D94-9BA1-A8228DF89A1BQ41969924-E81351BB-32BC-46D7-A80D-F6CD82A68295Q50277392-D9203658-3597-4F8E-AA3E-A9E2431BA059Q50942246-CA08CEAD-4EB6-4A50-8112-D0E0D1FE471EQ53087536-EADCEDE3-23CA-4114-8C35-4B8B7BA56418Q55642634-BFFF6152-31BD-48E7-8560-3AAB612FBF2A
P2860
MEK inhibitors as a chemotherapeutic intervention in multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
MEK inhibitors as a chemotherapeutic intervention in multiple myeloma.
@en
type
label
MEK inhibitors as a chemotherapeutic intervention in multiple myeloma.
@en
prefLabel
MEK inhibitors as a chemotherapeutic intervention in multiple myeloma.
@en
P2093
P2860
P356
P1433
P1476
MEK inhibitors as a chemotherapeutic intervention in multiple myeloma.
@en
P2093
C Chang-Yew Leow
S Gerondakis
P2860
P2888
P356
10.1038/BCJ.2013.1
P577
2013-03-22T00:00:00Z
P5875
P6179
1024602453